Cargando…

Synergistic and antagonistic AML cell type-specific responses to 5-AZA-2’-Deoxycytidine and 1-H-D-Arabinofuranosylcytosine

Detalles Bibliográficos
Autores principales:	Elmoneim, Abeer Abd, Heuston, Elisabeth, Wai, Daniel H, Trich, Timothy, Arceci, Robert J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075595/ http://dx.doi.org/10.1186/1471-2164-15-S2-P28

Ejemplares similares

Synergistic activity of everolimus and 5‐aza‐2′‐deoxycytidine in medullary thyroid carcinoma cell lines
por: Vitale, Giovanni, et al.
Publicado: (2017)

Monitoring of Intracellular l‐βD‐Arabinofuranosylcytosine 5′‐Triphosphate in 1‐β‐D‐Arabinofuranosylcytosine Therapy at Low and Conventional Doses
por: Yamauchi, Takahiro, et al.
Publicado: (2001)

Antitumor Activity and Pharmacology of 1‐β‐D‐Arabinofuranosylcytosine‐5′‐stearylphosphate: An Orally Active Derivative of 1‐β‐D‐Arabinofuranosylcytosine
por: Kodama, Kenjiro, et al.
Publicado: (1989)

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
por: Richel, D. J., et al.
Publicado: (1991)

5-Aza-2′-deoxycytidine stress response and apoptosis in prostate cancer
por: Patra, Aditi, et al.
Publicado: (2011)

Epigenetic regulation of the circadian clock: role of 5-aza-2′-deoxycytidine
por: Tomita, Tatsunosuke, et al.
Publicado: (2017)

Effect of Sulforaphane and 5-Aza-2’-Deoxycytidine on Melanoma Cell Growth
por: Chiang, Tung-chin, et al.
Publicado: (2019)

The Beginning of the Road for Non-Coding RNAs in Normal Hematopoiesis and Hematologic Malignancies
por: Heuston, Elisabeth F., et al.
Publicado: (2011)

Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer
por: Lemaire, Maryse, et al.
Publicado: (2008)

5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1
por: Maslov, Alexander Y., et al.
Publicado: (2012)

AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine
por: Tsai, Chiou-Tsun, et al.
Publicado: (2013)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
por: Konopleva, Marina, et al.
Publicado: (2023)

Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.
por: Horber, D. H., et al.
Publicado: (1995)

Administration of a vasoactive intestinal peptide antagonist significantly enhances the autologous anti-leukemia T cell response in a murine model of AML
por: Petersen, Christopher, et al.
Publicado: (2015)

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer
por: Meng, F, et al.
Publicado: (2013)

Sequential treatment with 5‐aza‐2′‐deoxycytidine and deacetylase inhibitors reactivates HIV‐1
por: Bouchat, Sophie, et al.
Publicado: (2015)

DNA demethylation caused by 5-Aza-2′-deoxycytidine induces mitotic alterations and aneuploidy
por: Costa, Giuseppe, et al.
Publicado: (2016)

Induction of MAGE Genes in Lymphoid Cells by the Demethylating Agent 5‐Aza‐2′‐deoxycytidine
por: Shichijo, Shigeki, et al.
Publicado: (1996)

Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2′-deoxycytidine in Hepatic Stellate Cells
por: Asada, Kiyoshi, et al.
Publicado: (2020)

Effects of 5-aza-2´-deoxycytidine on primary human chondrocytes from osteoarthritic patients
por: Kadler, Shirin, et al.
Publicado: (2020)

The Methylation Inhibitor 5-Aza-2′-Deoxycytidine Induces Genome-Wide Hypomethylation in Rice
por: Liu, Shuo, et al.
Publicado: (2022)

Combined Treatment with Valproic Acid and 5-Aza-2′-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration
por: Xi, Wenjin, et al.
Publicado: (2018)

Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2′-Deoxycytidine Against Pancreatic Cancer
por: Kong, Rui, et al.
Publicado: (2020)

Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia.
por: Richel, D. J., et al.
Publicado: (1988)

The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions
por: Orta, Manuel Luis, et al.
Publicado: (2014)

Isoform switching and exon skipping induced by the DNA methylation inhibitor 5-Aza-2′-deoxycytidine
por: Ding, Xiao-Lei, et al.
Publicado: (2016)

Global Demethylation of Rat Chondrosarcoma Cells after Treatment with 5-Aza-2′-Deoxycytidine Results in Increased Tumorigenicity
por: Hamm, Christopher A., et al.
Publicado: (2009)

Adoptive immunotherapy for AML with CD123-engager T cells
por: Bonifant, Challice, et al.
Publicado: (2015)

5-Azacytidine and 5-aza-2'-deoxycytidine behave as different antineoplastic agents in B16 melanoma.
por: Cortvrindt, R., et al.
Publicado: (1987)

Epigenetic Therapy of Non-Small Cell Lung Cancer Using Decitabine (5-Aza-2′-Deoxycytidine)
por: Momparler, Richard L.
Publicado: (2013)

A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
por: Momparler, Richard L.
Publicado: (2012)

Gene expression profiling of the synergy of 5-aza-2(′)-deoxycytidine and paclitaxel against renal cell carcinoma
por: Han, Tiandong, et al.
Publicado: (2012)

Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine in anaplastic large cell lymphoma
por: Hassler, Melanie R., et al.
Publicado: (2012)

DNA demethylation by 5-aza-2′-deoxycytidine is imprinted, targeted to euchromatin, and has limited transcriptional consequences
por: Ramos, María-Paz, et al.
Publicado: (2015)

The Cockayne syndrome protein B is involved in the repair of 5-AZA-2′-deoxycytidine-induced DNA lesions
por: Burgos-Morón, Estefanía, et al.
Publicado: (2018)

Close Correlation of 1‐β‐D‐Arabinofuranosylcytosine 5′‐Triphosphate, an Intracellular Active Metabolite, to the Therapeutic Efficacy of N(4)‐Behenoyl‐1‐β‐D‐arabinofuranosylcytosine Therapy for Acute Myelogenous Leukemia
por: Yamauchi, Takahiro, et al.
Publicado: (2001)

Significance of gain and loss of chromosomal abnormalities in AML: an Indian experience
por: Trivedi, Pina J, et al.
Publicado: (2014)

P55. Dendritic cell vaccination for postremission therapy in AML
por: Lichtenegger, FS, et al.
Publicado: (2014)

The Effect of 5-aza,2’-deoxyCytidine (5 AZA CdR or Decitabine) on Extrinsic, Intrinsic, and JAK/STAT Pathways in Neuroblastoma and Glioblastoma Cells Lines
por: Sanaei, Masumeh, et al.
Publicado: (2023)

P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS
por: Lopes De Menezes, Daniel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_obvdtoumi52jc3tutt6aptqkl6